Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

6.02
-0.5500-8.37%
Post-market: 6.080.0649+1.08%19:59 EST
Volume:10.64M
Turnover:65.68M
Market Cap:6.38B
PE:-5.60
High:6.53
Open:6.41
Low:6.00
Close:6.57
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.82
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0752
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.37%
PB:-5.57
PE(LYR):-15.76

Loading ...

Movement Alert|ImmunityBio, Inc. Falls 4.26% in Regular Trading, Q3 miss and wider loss continue to weigh on shares

Market Focus
·
Nov 20

Why ImmunityBio (IBRX) Stock Is Up 7.0% And What's Next After Bladder Cancer Trial Results

Simply Wall St.
·
Nov 19

Movement Alert|ImmunityBio, Inc. Intraday Rise 4.31% in Regular Trading, Anktiva overseas rollout and clinical progress support sentiment

Market Focus
·
Nov 18

ImmunityBio (IBRX) Could Be 56% Below Fair Value Following ANKTIVA Trial And Launch News

Simply Wall St.
·
Nov 18

Movement Alert|ImmunityBio, Inc. Intraday Rise 4.26% in Regular Trading, Anktiva overseas rollout and trial progress support sentiment

Market Focus
·
Nov 17

Movement Alert|ImmunityBio, Inc. falls 4.14% in Regular Trading, Q3 miss and wider loss continue to weigh on shares

Market Focus
·
Nov 16

Movement Alert|ImmunityBio, Inc. Intraday Decline 6%, Q3 loss expansion and revenue miss continued to pressure shares

Market Focus
·
Nov 12

Is ImmunityBio (IBRX) Getting Too Rich For Its Sales Story?

Simply Wall St.
·
Nov 12

OptimizeRx Q3 Sales Fall on Contracted Revenue; Lowers Annual Revenue Outlook

Reuters
·
Nov 12

ImmunityBio Survey Finds 63% of Military Bladder Cancer Patients Face Treatment Barriers

Reuters
·
Nov 11

ImmunityBio Stock Has The Bull Case Changed After Going Concern Warning?

Simply Wall St.
·
Nov 11

ImmunityBio Participates in Jefferies and UBS Healthcare Conferences

Reuters
·
Nov 11

Movement Alert|ImmunityBio, Inc. Falls 5.2% in Regular Trading, Q3 Loss Widened and Revenue Missed Expectations

Market Focus
·
Nov 11

Legend Biotech Q3 Revenue Rises Slightly Less than Expected

Reuters
·
Nov 10

Liquidia Q3 Loss Widens on Litigation Charge, Negating Yutrepia Demand

Reuters
·
Nov 10

NASDAQ Net Change Percentage Gainers & Losers

Dow Jones
·
Nov 10

GeneDx Q3 Revenue Beats on Higher Exome and Genome Test Volumes

Reuters
·
Nov 10

ImmunityBio falls -18.3%

TIPRANKS
·
Nov 10

ImmunityBio Reports Wider Quarterly Loss

Benzinga Earnings
·
Nov 09

Immunitybio Shares Down 24.5% After Co Reports Q3 Net Loss

THOMSON REUTERS
·
Nov 09